RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers
more
Stories about Forschung
Maria-Elena Torres-Padilla Honored With the Leibniz Prize 2025
more
25The Future of Nutrition: Dr. Clemens Röhrl on Regional Plant Research and Its Importance for Health and the Environment
moreAustria is a hotspot: 25 practical labs for the circular economy
Graz, Austria (ots) - With more than 25 test labs in Austria, the first-ever “Circularity Labs Austria” map demonstrates a concentration in the field of the circular economy that is probably unique in Europe. Most of them, and almost all of them on an industrial, large-scale, are located around the University of Leoben. Companies from Austria and abroad are testing here which raw materials from waste can be used in ...
moreGrünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...
moreDeutsche Bundesstiftung Umwelt (DBU)
Encouraging people to protect the earth / DBU honours Franziska Tanneberger and Thomas Speidel
Osnabrück, Germany (ots) - Ways to better protect the planet are currently being debated at the World Summit on Nature in Cali, Colombia, and soon at the World Climate Conference in Baku, Azerbaijan. Today in Mainz, two people are demonstrating what practical solutions can look like: Peatland researcher Dr Franziska Tanneberger and electrical engineer Thomas Speidel ...
moreFirst participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...
moreExtreme Rainfall Poses Health Risks
Extreme Rainfall Poses Health Risks An international study led by Helmholtz Munich investigates the health consequences of heavy rainfall events. Researchers analyzed the relationship between precipitation patterns and mortality rates at 645 locations across 34 countries from 1980 to 2020. The key finding: Extremely heavy rainfall, which occurs approximately every five years, significantly increases the risk of death, ...
morecanSERV relaunches Open Call for Service Provision
One documentmoreAcousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferences
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston (MA) from August ...
moreESSL - European Severe Storms Laboratory
Europe needs Twisters campaign
Wiener Neustadt, Austria (ots) - Researchers from all over Europe are organising high-density measurements of severe storms, similar to the new film Twisters. Severe weather researchers from 14 European countries want to work together to get to the bottom of severe thunderstorms so that they can provide better warnings in future. To this aim, they are currently planning the largest European measurement campaign on severe thunderstorms to date. "We want to use the latest ...
moreRenowned Public Health Expert Prof. Siegal Sadetzki Joins Briya
Tel Aviv, Israel (ots/PRNewswire) - Briya, a leading medical data retrieval network, proudly announces the appointment of Prof. Siegal Sadetzki as Chief Epidemiology Officer. With over three decades of experience in public health and epidemiology, Prof. Sadetzki brings a wealth of expertise to Briya's mission of making medical data accessible for research at scale and assisting hospitals in optimizing their data ...
morePress Release: Restless Legs Syndrome: Genetic Discoveries Advance Treatment and Risk Prediction
Researchers at Helmholtz Munich and the Technical University of Munich (TUM) together with international collaborators have conducted the largest genetic investigation of the restless legs syndrome to date. Their findings, ...
moreKontrast Personalberatung GmbH
Postdocs for Core Informatics & PhD Students for Cyber-Physical Systems Wanted
Hamburg (ots) - Karlsruhe Institute of Technology launches two innovative research projects in cooperation with the Helmholtz Association The Karlsruhe Institute of Technology (KIT), one of Europe's leading technical universities, announces the launch of two groundbreaking research projects, which set new standards in basic research on cyber-physical systems and core ...
moreResearchers: The future of democracy is on the ballot in Europe
morecanSERV invites applications for "Revolutionising Cancer Patient Care"
One documentmoreLAST CHANCE: canSERV Second Open Call for Cancer Research Service Provision
One documentmoreBosch Healthcare Solutions GmbH
Bosch and Randox: Strategic partnership brings highly multiplexing PCR to the point of care / BioMEMS technology enables fully automated, simultaneous testing for hundreds of genetic characteristics in just a few minutes
Waiblingen (ots) - - Bosch and Randox Laboratories Ltd. enter partnership for Vivalytic analysis platform to jointly invest around 150 million euros. - First test to feature novel BioMEMS technology will be a highly multiplexing sepsis IVD grade test. Bosch has agreed on a strategic partnership with Randox ...
moreDr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatment
moreARTCLINE successfully completes capital increases of EUR 4.4 million
Rostock, Germany (ots) - Today ARTCLINE GmbH announced the successful completion of two further capital increases. In addition to the founders, in particular family offices from Germany participated in the first capital increase of EUR 0.8 million. In addition, a convertible loan from investors was transferred to equity, so that a second capital increase of EUR 3.6 ...
more2022 Marked a Record for German R&D Investments
Berlin (ots) - EUR 121.4 billion was spent in Germany on reasearch and development - more than ever before in a single year. According to the Federal Statistical Office, the amount of money devoted to R&D rose by seven percent in 2022, reaching an all-time high. The figures include commercial, university and non-university research. R&D investments by businesses grew by eight percent, reaching EUR 81.8 billion. That's ...
more- 4
FDX Fluid Dynamix and Fraunhofer IPK to Collaborate with Lonza on Novel Nanoparticle Formulation Technology Platform FDmiX
more Research Success in Rare Disease / RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease‘
moreLTS Lohmann Therapie-Systeme AG
First product based on LTS’ Sorrel(TM) wearable drug delivery platform launched in the US
moreWhat Our Genetic Information Tells Us About Type 2 Diabetes Risk and Complications
moreUniversità degli studi di Milano - Bicocca
Early Smartphone Use in Children? Two Studies Highlight Long-Term Consequences
Milan (ots) - A group of researchers from the University of Milano-Bicocca and SUPSI, by means of longitudinal data provided by INVALSI (Italian Institute for the Evaluation of the Education System), has confirmed that early smartphone usage before the age of 12 does not bring benefits. Instead, it is associated with lower digital skills, higher problematic smartphone ...
moreThe ocean – a climate champion? How to boost marine carbon dioxide uptake
moreLTS Lohmann Therapie-Systeme AG
LTS receives $4.3 Million grant for the development of contraceptive Microneedle Array Patches
more- 2
PIONEER+ becomes Big Data Platform for Prostate Cancer of the EAU's UroEvidenceHub
more - 3
EU Provides 1 Mio. to Researchers to Advance Personalised Oncology
One documentmore
1234Next